Topical Sirolimus in Patients With Basal Cell Nevus Syndrome and in Healthy Participants
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00433485|
Recruitment Status : Completed
First Posted : February 12, 2007
Last Update Posted : September 23, 2016
RATIONALE: Studying samples of blood and tissue from patients with basal cell nevus syndrome and from healthy participants in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to basal cell nevus syndrome. Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of sirolimus may keep basal cell skin cancer from forming in patients with basal cell nevus syndrome.
PURPOSE: This phase I trial is studying topical sirolimus in patients with basal cell nevus syndrome and in healthy participants.
|Condition or disease||Intervention/treatment||Phase|
|Neoplastic Syndrome Non-melanomatous Skin Cancer||Drug: sirolimus Genetic: comparative genomic hybridization Genetic: gene expression analysis Genetic: microarray analysis Genetic: protein expression analysis Genetic: proteomic profiling Other: laboratory biomarker analysis Other: mass spectrometry Procedure: biopsy||Phase 1|
- Compare messenger RNA and protein expression patterns in patients with basal cell nevus syndrome (BCNS) vs in cultured cells of healthy participants (control) before treatment to identify a set of genes that are differentially expressed in BCNS.
- Assess the effects of topical sirolimus on gene expression (genes identified in the primary objective) in vivo using keratinocytes, fibroblasts, and lymphocytes from patients with BCNS and from healthy participants (controls) by targeted expression methods.
OUTLINE: Patients and healthy participants receive topical sirolimus ointment twice daily for 12 weeks.
Blood and skin biopsies are obtained at baseline and at week 12 for gene and protein expression studies. Alterations in RNA are measured by microarray analysis. Alterations in protein expression are measured by 2-dimensional gel electrophoresis and matrix-assisted laser desorption ionization time-of-flight mass spectrometry.
After completion of study therapy, patients and healthy participants are followed at 4 weeks.
PROJECTED ACCRUAL: A total of 16 patients and healthy participants will be accrued for this study.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||16 participants|
|Masking:||None (Open Label)|
|Official Title:||In Vivo and In Vitro Pharmacology of Sirolimus in Subjects With Basal Cell Nevus Syndrome|
|Actual Primary Completion Date :||March 2008|
|Actual Study Completion Date :||March 2008|
U.S. FDA Resources
- Alterations in RNA as measured by microarray analysis
- Alterations in protein expression as measured by 2-dimensional gel electrophoresis and matrix-assisted laser desorption ionization time-of-flight mass spectroscopy
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00433485
|Principal Investigator:||Allen E. Bale, MD||Yale University|